Tesamorelin / Ipamorelin
This combination pairs Tesamorelin — a GHRH analog with FDA-approved clinical trial data behind it — with Ipamorelin, a selective ghrelin-receptor agonist, to stimulate growth hormone release through two distinct, complementary pathways.
- Combines an FDA-drug-basis GHRH analog with a selective GH secretagogue
- May support GH release and body composition
- Designed to work through two complementary pathways
No commitment · Cancel anytime · Physician evaluation required
About Tesamorelin / Ipamorelin
Tesamorelin activates GHRH receptors on the pituitary; Ipamorelin activates a separate ghrelin receptor pathway. Combining a GHRH analog with a ghrelin-receptor secretagogue is a well-established pharmacological strategy for amplifying pulsatile GH release beyond what either compound achieves alone.
What the research shows
Tesamorelin itself has the strongest evidence base of any GH-pathway peptide in this catalog, backed by FDA-approved Phase 3 trial data (Falutz et al., NEJM 2007) for visceral fat reduction. Ipamorelin's human pharmacology was established by Raun et al. (1998), describing it as a highly selective GH secretagogue that does not significantly raise cortisol, prolactin, or ACTH — a cleaner hormonal profile than older GH-releasing peptides. The specific combination has not been studied together in a dedicated large trial; the rationale rests on the individual pharmacology of each component.
Who it's for
This combination is generally considered by adults interested in body composition and recovery support who want a dual-pathway approach to GH stimulation.
How It's Administered
Both peptides are typically administered as subcutaneous injections. Your physician will determine dosing and timing during your evaluation, often based on established GHRH/GHS combination protocols.
Safety & Considerations
Reported effects draw on each component's individual trial data: tesamorelin's Phase 3 program documented injection site reactions and joint discomfort as most common; ipamorelin's studies report a favorable side-effect profile at therapeutic doses, without the cortisol/prolactin/appetite effects seen with older-generation GH secretagogues.
Your physician will review your full health history during your evaluation. Not all applicants will qualify.
Selected References
The following peer-reviewed sources informed the summary above. Evidence quality varies — some reflect large controlled human trials, others early-stage or animal research, as noted.
- Falutz J, et al. Effects of tesamorelin on visceral fat and liver fat in HIV patients
New England Journal of Medicine, 2007 (PMID 18057338) - Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue
European Journal of Endocrinology, 1998